Abstract
Hepatitis C virus infection remains prevalent in dialysis patients and renal transplant recipients. Treatment of HCV in patients with chronic kidney disease (CKD) is predicated on the premise that HCV is associated with decreased patient survival. All CKD patients with HCV should be evaluated for antiviral treatment and the decision to treat be based on potential benefits and risks of therapy (including life expectancy, candidacy for kidney transplantation, and comorbidities). There is good information supporting the antiviral treatment of HCV-infected renal transplant candidates; in these patients the goals of antiviral therapy include to avoid HCV-related extra-hepatic complications after RT (i.e., de novo glomerulonephritis, new onset diabetes after transplant, infections, and chronic allograft nephropathy). The summary estimate of sustained virological response (SVR) and drop-out rate to monotherapy with standard or pegylated interferon in dialysis patients, according to recent meta-analyses, is around 33–37 and 17–23% respectively. Recent data support the use of ribavirin in the dialysis setting, after implementation of some safety precautions. The summary estimate for sustained viral response in patients receiving IFN plus ribavirin was 56% (95% CI, 28–84). No data are available yet to confirm that achieving SVR translates into improved survival in the CKD population with HCV infection. However, successful antiviral therapy can improve other outcomes (e.g., liver histology). Pretransplant liver biopsy is crucial to determine the severity of hepatic injury and thereby to assess the prognosis of the patient. Antiviral therapy is virtually contraindicated after renal transplantation as the frequency of acute rejection induced by IFN is great (up to 50%). Kidney transplantation should be considered the treatment of choice for patients with CKD stage 5 and HCV. A risk related to the use of kidneys from HCV-positive donors cannot be excluded.
Keywords
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Choo QL, Kuo G, Weiner AJ, et al. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science. 1989;244:359–62.
Kuo G, Choo QL, Alter HJ, et al. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science. 1989;244:362–4.
Fabrizi F, Lunghi G, Ganeshan V, Martin P, Messa P. Hepatitis C virus infection and the dialysis patient. Semin Dial. 2007;20:416–22.
Finelli L, Miller JT, Tokars JI, Alter MJ, Arduino MJ. National surveillance of dialysis-associated diseases in the United States, 2002. Semin Dial. 2005;18:52–61.
Fabrizi F, Takkouche B, Lunghi G, Dixit V, Messa P, Martin P. The impact of hepatitis C virus infection on survival in dialysis patients: meta-analysis of observational studies. J Viral Hepat. 2007;14:697–703.
Kalantar-Zadeh K, Kilpatrick RD, McAllister CJ, Miller LG, Daar ES, Gjertson DW, et al. Hepatitis C virus and death risk in haemodialysis patients. J Am Soc Nephrol. 2007;18:1584–93.
Fabrizi F, Martin P, Dixit V, Bunnapradist S, Dulai G. Hepatitis C virus antibody status and survival after renal transplantation: meta-analysis of observational studies. Am J Transplant. 2005;6:1452–61.
Kidney Disease: Improving Global Outcomes. KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of Hepatitis C in chronic kidney disease. Kidney Int. 2008;73 Suppl 109:S1–99.
Cruzado JM, Casanovas-Taltavull T, Torras J, et al. Pre-transplant interferon prevents hepatitis C virus-associated glomerulonephritis in renal allografts by HCV-RNA clearance. Am J Transplant. 2003;3:357–60.
Mahmoud IM, Sobh MA, El-Habashi AF, et al. Interferon therapy in haemodialysis patients with chronic hepatitis C: study of tolerance, efficacy and post-transplantation course. Nephron Clin Pract. 2005;100:c133–9.
Gursoy M, Guvener N, Koksal R, et al. Impact of HCV infection on development of post-transplantation diabetes mellitus in renal allograft recipients. Transplant Proc. 2000;35:1748–50.
Mathurin P, Mouquet C, Poynard T, et al. Impact of hepatitis B and C virus on kidney transplantation outcome. Hepatology. 1999;29:257–63.
Pol S, Carnot F, Nalpas B, et al. Reversibility of hepatitis C virus-related cirrhosis. Hum Pathol. 2004;35:107–12.
Fabrizi F, Dixit V, Messa P, Martin P. Interferon monotherapy of chronic hepatitis C in dialysis patients: meta-analysis of clinical trials. J Viral Hepat. 2008;15:79–88.
Rostaing L, Chatelut E, Payen JL, et al. Pharmacokinetics of alphaIFN-2b in chronic hepatitis C virus patients undergoing chronic haemodialysis or with normal renal function: clinical implications. J Am Soc Nephrol. 1998;9:2344–8.
Badalamenti S, Catania A, Lunghi G, et al. Changes in viraemia and circulating interferon-alpha during haemodialysis in hepatitis C virus-positive patients: only coincidental phenomena? Am J Kidney Dis. 2003;42:143–50.
Barril G, Bartolomè J, Sanz P, Buoncristiani E, Traver JA, Selgas R, et al. Effect of haemodialysis schedules and membranes on hepatocyte growth factor and hepatitis C virus RNA levels. J Med Virol. 2010;82:763–7.
Fabrizi F, Dixit V, Messa P, Martin P. Pegylated interferon mono-therapy of chronic hepatitis C in dialysis patients: meta-analysis of clinical trials. J Med Virol. 2010;82:768–75.
Toth CM, Pascual M, Chung RT, et al. Hepatitis C virus-associated fibrosing cholestatic hepatitis after renal transplantation: response to interferon-alpha therapy. Transplantation. 1998;66:1254–8.
Fontaine H, Vallet-Pichard A, Equi-Andrade C, Nalpas B, Verkarre C, Chaix ML, et al. Histo-pathological efficacy of ribavirin monotherapy in kidney allograft recipients with chronic hepatitis C. Transplantation. 2004;78:853–7.
Kamar N, Rostaing L, Sandres-Saune K, et al. Amantadine therapy in renal transplant patients with hepatitis C virus infection. J Clin Virol. 2004;30:110–4.
Russo MW, Goldsweig C, Iacobson M, Brown RS. Interferon monotherapy for dialysis patients with chronic hepatitis C: an analysis of the literature on efficacy and safety. Am J Gastroenterol. 2003;98:1610–5.
Fabrizi F, Dixit V, Martin P, Messa P. Combined antiviral therapy of HCV in dialysis patients: meta-analysis of clinical trials. J Viral Hepat. 2011;18(7):e263–9. doi: 10.1111/j.1365-2893.2010.01405.x.
Bruchfeld A, Lindahl K, Reichard O, Carlsson T, Schvarcz R. Pegylated interferon and ribavirin treatment for hepatitis C in haemodialysis patients. J Viral Hepat. 2006;13:316–21.
Rendina M, Castellaneta NM, Castellaneta A, Losito A, Schena A, Stallone G, et al. The treatment of chronic hepatitis C with peginterferon alpha2a (40 kDA) plus ribavirin in haemodialysed patients awaiting renal transplant. J Hepatol. 2007;46:764–8.
Schmitz V, Kiessling A, Bahra M, Puhl G, Kahl A, Berg T, et al. Peginterferon alfa-2b plus ribavirin for the treatment of hepatitis C recurrence following combined liver and kidney transplantation. Ann Transplant. 2007;12:22–7.
van Leusen R, Adang RP, de Vries RA, Cnossen TT, Konings CJ, Schalm SW, et al. Pegylated interferon alfa-2a (40kD) and ribavirin in haemodialysis patients with chronic hepatitis C. Nephrol Dial Transplant. 2008;23:721–5.
Carriero D, Fabrizi F, Uriel A, Park J, Martin P, Dieterich DT. Treatment of dialysis patients with chronic hepatitis C using pegylated-interferon and low dose ribavirin. Int J Artif Organs. 2008;31:295–302.
Hakim W, Sheikh S, Inayat I, Caldwell C, Smith D, Lorber M, et al. HCV response in patients with end stage renal disease treated with combination pegylated interferon alpha-2a and ribavirin. J Clin Gastroenterol. 2009;43:477–81.
Pereira BJ, Natov SN, Bouthot BA, et al. Effects of hepatitis C infection and renal transplantation on survival in end-stage renal disease. The New England Organ Bank Hepatitis C Study Group. Kidney Int. 1998;53:1374–81.
Knoll GA, Tankersley MR, Lee JY. The impact of renal transplantation on survival in hepatitis C-positive end-stage renal disease patients. Am J Kidney Dis. 1997;29:608–14.
Bloom RD, Sayer G, Fa K, et al. Outcome of hepatitis C virus-infected kidney transplant candidates who remain on the waiting list. Am J Transplant. 2005;5:139–44.
Ali MK, Light JA, Barhyte DY, et al. Donor hepatitis C virus status does not adversely affect short-term outcomes in HCV positive recipients in renal transplantation. Transplantation. 1998;66:1694–7.
Morales JM, Campistol JM, Andres A, et al. Policies concerning the use of kidneys from donors infected with hepatitis C virus. Nephrol Dial Transplant. 2000;15:S71–3.
Mandal AK, Kraus ES, Samaniego M, et al. Shorter waiting times for hepatitis C virus seropositive recipients of cadaveric renal allografts from hepatitis C virus seropositive donors. Clin Transplant. 2000;14:391–6.
Abbott KC, Bucci JR, Matsumoto CS, Swanson SJ, Agodoa CY, Holtzmuller KC, et al. Hepatitis C and renal transplantation in the era of modern immunosuppression. J Am Soc Nephrol. 2003;14:2908–18.
Abbott KC, Lentine KL, Bucci JR, et al. Impact of diabetes and hepatitis after kidney transplantation on patients who are affected by hepatitis C virus. J Am Soc Nephrol. 2004;15:3166–74.
Widell A, Mansson S, Persson NH, et al. Hepatitis C super-infection in hepatitis C virus-infected patients transplanted with an HCV-infected kidney. Transplantation. 1995;60:642–7.
Schussler T, Staffeld-Coit C, Eason J, Nair S. Severe hepatitis C infection in a renal transplant recipient following hepatitis C genotype mismatch transplant. Am J Transplant. 2004;8:1375–80.
Acknowledgements
This work has been supported in part by the grant “Project Glomerulonephritis” in memory of Pippo Neglia.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Martin, P., Fabrizi, F. (2012). Chronic HCV in Patients with Renal Disease. In: Shiffman, M. (eds) Chronic Hepatitis C Virus. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-1192-5_8
Download citation
DOI: https://doi.org/10.1007/978-1-4614-1192-5_8
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-1191-8
Online ISBN: 978-1-4614-1192-5
eBook Packages: MedicineMedicine (R0)